In vitro fluoroquinolone susceptibility of Pseudomonas aeruginosa isolates from dogs with ulcerative keratitis

American Journal of Veterinary Research

Volumn 68, Issue 6, 2007, Pages 638-642

  Ledbetter, Eric C ^a   Hendricks, Linda M ^b   Riis, Ronald C ^a   Scarlett, Janet M ^a  

^a Department of Molecular Biology and Genetics   (United States)

^b Cayuga Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CONTROLLED STUDY; DOG DISEASE; IN VITRO STUDY; KERATITIS; NONHUMAN; PSEUDOMONAS AERUGINOSA; SENSITIVITY ANALYSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; CORNEAL ULCER; DOG DISEASES; DOGS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

ANIMALIA; BACTERIA (MICROORGANISMS); CANIS FAMILIARIS; PSEUDOMONAS AERUGINOSA;

EID: 34447333428     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.68.6.638     Document Type: Article

References (48)

1. Drlica K. Mechanism of fluoroquinolone action. Curr Opin Microbiol 1999;2:504-508.
2. McGee DH, Holt WF, Kastner PR, et al. Safety of moxifloxacin as shown in animal and in vitro studies. Surv Ophthalmol 2005;50: S46-S54.
3. Kowalski RP, Dhaliwal DK, Karenchak LM, et al. Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol 2003;136:500-505.
4. Guzek JP, Chacko D, Kettering JD, et al. Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of experimental Pseudomonas aeruginosa keratitis. Cornea 1994;13:500-504.
5. Tolar EL, Hendrix DV, Rohrbach BW, et al. Evaluation of clinical characteristics and bacterial isolates in dogs with bacterial keratitis: 97 cases (1993-2003). J Am Vet Med Assoc 2006;228:80-85.
6. Sauer P, Andrew SE, Lassaline M, et al. Changes in antibiotic resistance in equine bacterial ulcerative keratitis (1991-2000): 65 horses. Vet Ophthalmol 2003;6:309-313.
7. Ince D, Hooper DC. Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus. Antimicrob Agents Chemother 2001; 45:2755-2764.
8. Fung-Tomc J, Minassian B, Kolek B, et al. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin. J Antimicrob Chemother 2000;24:437-446.
9. Saravolatz LD, Leggett J. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. Clin Infect Dis 2003;37:1210-1215.
10. Blondeau JM, Laskowski R, Bjarnason J, et al. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 gram-negative and gram-positive organisms. Int J Antimicrob Agents 2000;14:45-50.
11. Kowalski RP, Pandya AN, Karenchak LM, et al. An in vitro resistance study of levofloxacin, ciprofloxacin, and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa. Ophthalmology 2001;108:1826-1829.
12. Thibodeaux BA, Dajcs JJ, Caballero AR, et al. Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis. Curr Eye Res 2004;28:337-342.
13. Jensen H, Zerouala C, Carrier M, et al. Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits. J Ocul Pharmacol Ther 2005;21:36-43.
14. Robertson SM, Curtis MA, Schlech BA, et al. Ocular pharmaco-kinetics of moxifloxacin after topical treatment in animals and humans. Surv Ophthalmol 2005;50(suppl 1):S32-S45.
15. Kreger AS. Pathogenesis of Pseudomonas aeruginosa ocular diseases. Rev Infect Dis 1983;5(suppl 5):931-935.
16. Gerding PA Jr, McLaughlin SA, Troop MW. Pathogenic bacteria and fungi associated with external ocular disease in dogs: 131 cases (1981-1986). J Am Vet Med Assoc 1988;193:242-244.
17. Fleiszig SM, Evans DJ. The pathogenesis of bacterial keratitis: studies with Pseudomonas aeruginosa. Clin Exp Optom 2002;85:271-278.
18. Wyman M, Swanson C, Kowalski JJ, et al. Experimental Pseudomonas aeruginosa ulcerative keratitis model in the dog. Am J Vet Res 1983;44:1135-1140.
19. Van Horn DL, Davis SD, Hyndiuk RA, et al. Experimental Pseudomonas keratitis in the rabbit: bacteriologic, clinical, and microscopic observations. Invest Ophthalmol Vis Sci 1981;20:213-221.
20. Sweeney CR, Irby NL. Topical treatment of Pseudomonas sp-infected corneal ulcers in horses: 70 cases (1977-1994). J Am Vet Med Assoc 1996;209:954-957.
21. Kroll P, Busse H. A case of total keratomalacia due to soft contact lens wearing. Ann Ophthalmol 1980;12:1374-1376.
22. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006;43:S49-S56.
23. Lee EJ, Truong TN, Mendoza MN, et al. A comparison of invasive and cytotoxic Pseudomonas aeruginosa strain-induced corneal disease responses to therapeutics. Curr Eye Res 2003;27:289-299.
24. National Committee for Clinical Laboratory Standards. In: Performance standards for antimicrobial disk susceptibility tests; approved standard M2-A. 9th ed. Wayne, Pa: Clinical and Laboratory Standards Institute, 2006;1-35.
25. Kowalski RP, Yates KA, Romanowski EG, et al. An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data. Ophthalmology 2005;112:1987e1-1987e6.
26. Romanowski EG, Mah FS, Yates KA, et al. The successful treatment of gatifloxacin-resistant Staphylococcus aureus keratitis with Zymar (gatifloxacin 0.3%) in a NZW rabbit model. Am J Ophthalmol 2005;139:867-877.
27. Wilhelmus KR, Abshire RL, Schlech BA. Influence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitis. Arch Ophthalmol 2003;121:1229-1233.
28. Riddle C, Lemons CL, Papich MG, et al. Evaluation of ciprofloxacin as a representative of veterinary fluoroquinolones in susceptibility testing. J Clin Microbiol 2000;38:1636-1637.
29. Martin Barrasa JL, Lupiola Gomez P, Gonzalez Lama Z, et al. Antibacterial susceptibility patterns of Pseudomonas strains isolated from chronic canine otitis externa. J Ver Med B Infect Dis Vet Public Health 2000;47:191-197.
30. Polk RE,Johnson CK, McClish D, et al. Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin Infect Dis 2004;39:497-503.
31. Fridkin SK, Hill HA, Volkova NV, et al. Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals. Emerg Infect Dis 2002;8:697-701.
32. Tejedor MT, Martin JL, Navia M, et al. Mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from canine infections. Vet Microbiol 2003;94:295-301.
33. Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 2001;7:337-341.
34. Kriengkauykiat J, Porter E, Lomovskaya O, et al. Use of an efflux pump inhibitor to determine the prevalence of efflux pump-mediated fluoroquinolone resistance and multidrug resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005;49:565-570.
35. Thomas LE, Couetdic G, Clermont O, et al. In vivo selection of a target/ efflux double mutant of Pseudomonas aeruginosa by ciprofloxacin therapy J Antimicrob Chemother 2001;48:553-555.
36. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in South Florida and emerging resistance to fluoroquinolones. Ophthalmology 2000;107:1497-1502.
37. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology 1999;106:1313-1318.
38. Garg P, Sharrna S, Rao GN. Ciprofloxacin-resistant Pseudomonas keratitis. Ophthalmology 1999;106:1319-1323.
39. Rhee MK, Kowalski RP, Romanowski EG, et al. A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol 2004;138:226-230.
40. Moshirfar J, Mirzaizn G, Feiz V, et al. Fourth-generation fluoroquinolone-resistant bacterial keratitis after refractive surgery J Cataract Refract Surg 2006;32:515-518.
41. Chaudry NA, Flynn HW, Murray TG, et al. Emerging ciprofloxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol 1999;128:509-510.
42. Epstein SP, Bottone EJ, Asbell PA. Susceptibility testing of clinical isolates of Pseudomonas aeruginosa to levofloxacin, moxifloxacin, and gatifloxacin as a guide to treating Pseudomonas ocular infection. Eye Contact Lens 2006;32:240-244.
43. Song A, McCulley TJ, Lam BL, et al. Pseudomonas aeruginosa in vitro corneal isolate sensitivity to ofloxacin, ciprofloxacin, and trovafloxacin: a comparative study. Am J Ophthalmol 2001;131:795-796.
44. Kunimoto DY, Sharma S, Garg P, et al. In vitro susceptibility of bacterial keratitis pathogens to ciprofloxacin: emerging resistance. Ophthalmology 1999;106:80-85.
45. Lomholt JA, Kilian M. Ciprofloxacin susceptibility of Pseudomonas aeruginosa isolates from keratitis. Br J Ophthalmol 2003;87:1238-1240.
46. Hsu DI, Okamoto MP, Murthy R, et al. Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes. J Antimicrob Chemother 2005;55:535-541.
47. Burgess DS. Use of pharmokinetics and pharmacodynamics to optimize antimicrobial treatment of Pseudomonas aeruginosa infections. Clin Infect Dis 2005;40:S99-S104.
48. Nakano M, Yasuda M, Yokoi S, et al. In vivo selection of Pseudomonas aeruginosa with decreased susceptibilities to fluoroquinolones during fluoroquinolone treatment of urinary tract infection. Urology 2001;58:125-128.